Hostname: page-component-6766d58669-l4t7p Total loading time: 0 Render date: 2026-05-17T01:56:15.086Z Has data issue: false hasContentIssue false

Ipratropium bromide in the treatment of the ‘rhinorrhoea syndrome’

Published online by Cambridge University Press:  29 June 2007

T. P. O'Dwyer*
Affiliation:
Senior Registrar, Department of Otolaryngology, Eye & Ear Hospital, Dublin.
R. J. Lee
Affiliation:
Senior Registrar, Department of Otolaryngology, Federated Dublin Voluntary Hospitals.
J. Kaye
Affiliation:
Research Associate, Boehringer Ingelbeim Ltd., Bracknell.
G. Fennell
Affiliation:
Chief, Department of Otolaryngology, Eye & Ear Hospital, Dublin.
*
Mr. T. O'Dwyer, Royal Victoria Eye & Ear Hospital, Adelaide Road, Dublin 2, Ireland.

Abstract

Conventional treatments for non-allergic perennial rhinitis have proven somewhat unsuccessful in the control of rhinorrhoea when it is the predominant symptom. Hence, a double-blind cross-over trial of Ipratropium, a parasympatholytic, and placebo were carried out over a 12-week period. There was a significant reduction in rhinorrhoea during active treatment, with the most noticable effect being in the moderate-to-severe rhinorrhoea group. No significant effect was noted on nasal obstruction or sneezing and no serious side-effects were seen. A carry-on effect was noted when active treatment was used initially. However, the group given active treatment following placebo had a better result overall. A strong placebo effect was also noted in both groups, in keeping with a trial of this order.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable